Tabuk Pharmaceuticals Signs License and Supply Agreement With Selectchemie

AMMAN, Jordan, October 2, 2017 /PRNewswire/ --

Tabuk Pharmaceutical Manufacturing Company ("Tabuk"), one of the leading pharmaceutical companies in the Middle East and North Africa (MENA) region, has entered into an agreement with Selectchemie, under which Selectchemie granted Tabuk a license to register, market and sell Caspofungin Injection (systemic antifungal agent) in Saudi Arabia, the Gulf Countries, North Africa, and the rest of Middle East.

Selectchemie is one of the leading European companies, headquartered in Zurich serving the pharmaceutical and human nutrition industries since 1969 as a premier supplier of high quality ingredients.

Dr. Rana Azzam, Senior VP of Business Development said "We are excited about this major partnership collaboration with Selectchemie. Caspofungin Injection is a hard to develop and lifesaving product. This partnership will provide an opportunity for both companies to leverage their combined strength."

Selectchemie side commented "Dr. Peter Kaufmann, CEO of Selectchemie, is proud to have gained Tabuk Pharmaceutical Manufacturing Company as a licensing and marketing partner for Caspofungin in the MENA Region. With this highest quality product, manufactured in Europe, Selectchemie looks forward to a long-term partnership with Tabuk to the benefit of both companies and end-users."

SOURCE Tabuk Pharmaceuticals



Journalists and Bloggers

Visit PR Newswire for Journalists for releases, photos and customised feeds just for media.

View and download archived video content distributed by MultiVu on The Digital Center.

 

Get content for your website

Enhance your website's or blog's content with PR Newswire's customised real-time news feeds.
Start today.

 

 
 

Contact PR Newswire

Send us an email at info@prnewswire.co.il or call us at +972-77-2005042

 

 
 

Become a PR Newswire client

Send us an email at info@prnewswire.co.il or call us at +972-77-2005042

 

 
  1. Products & Services
  2. News Releases
  3. Contact Us